Novo Nordisk ROE 2010-2022 | NVO

Current and historical return on equity (ROE) values for Novo Nordisk (NVO) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Novo Nordisk ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2022-06-30 $7.63B $10.65B 71.98%
2022-03-31 $7.70B $10.04B 72.59%
2021-12-31 $7.60B $11.26B 72.62%
2021-09-30 $7.45B $10.49B 73.90%
2021-06-30 $7.14B $10.63B 72.93%
2021-03-31 $6.74B $9.48B 72.12%
2020-12-31 $6.46B $9.70B 71.80%
2020-09-30 $6.23B $9.35B 71.40%
2020-06-30 $6.13B $8.87B 73.35%
2020-03-31 $6.01B $8.04B 73.80%
2019-12-31 $5.84B $8.63B 73.63%
2019-09-30 $5.62B $7.89B 72.49%
2019-06-30 $5.51B $8.00B 72.19%
2019-03-31 $5.72B $7.20B 75.29%
2018-12-31 $5.91B $7.93B 77.47%
2018-09-30 $6.16B $7.41B 81.76%
2018-06-30 $6.30B $7.86B 83.53%
2018-03-31 $6.11B $7.30B 83.00%
2017-12-31 $5.79B $7.57B 82.96%
2017-09-30 $5.73B $7.42B 84.54%
2017-06-30 $5.65B $7.16B 87.38%
2017-03-31 $5.69B $5.78B 90.46%
2016-12-31 $5.64B $6.73B 90.49%
2016-09-30 $5.59B $6.20B 88.77%
2016-06-30 $5.37B $6.47B 84.50%
2016-03-31 $5.09B $5.51B 82.31%
2015-12-31 $5.19B $6.99B 86.16%
2015-09-30 $5.08B $6.43B 83.64%
2015-06-30 $4.98B $5.80B 81.00%
2015-03-31 $5.03B $4.87B 78.79%
2014-12-31 $4.72B $7.18B 70.33%
2014-09-30 $4.74B $6.76B 69.51%
2014-06-30 $4.72B $6.74B 68.77%
2014-03-31 $4.61B $6.17B 68.59%
2013-12-31 $4.49B $7.58B 67.16%
2013-09-30 $4.38B $6.95B 67.04%
2013-06-30 $4.20B $6.20B 66.63%
2013-03-31 $3.94B $5.99B 64.56%
2012-12-31 $3.70B $7.02B 61.39%
2012-09-30 $3.53B $5.99B 58.56%
2012-06-30 $3.36B $5.42B 54.13%
2012-03-31 $3.24B $5.71B 48.73%
2011-12-31 $3.16B $7.00B 46.43%
2011-09-30 $3.06B $6.73B 45.62%
2011-06-30 $2.94B $7.13B 45.21%
2011-03-31 $2.77B $6.38B 44.97%
2010-12-31 $2.62B $6.59B 42.96%
2010-09-30 $2.35B $5.93B 38.39%
2010-06-30 $2.23B $5.75B 35.31%
2010-03-31 $2.15B $6.12B 33.40%
2009-12-31 $2.03B $6.69B 32.40%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $215.616B $22.397B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $435.655B 16.59
Eli Lilly (LLY) United States $292.179B 37.05
AbbVie (ABBV) United States $249.673B 10.61
Pfizer (PFE) United States $245.989B 7.21
Merck (MRK) United States $218.318B 11.40
Novartis AG (NVS) Switzerland $165.082B 12.17